Loading...
Loading...
shares were trading sharply higher by $2.44 (9.5 percent) at $26.95 in Wednesday's session. There appears to be no relevant information from today that may explain the rally to a new all-time high ($27.83), eclipsing the former high from March 13 ($24.89) by a wide margin.
On Tuesday, Zacks upgraded shares of La Jolla Pharmaceutical from Hold to Buy with a $27 price target.
La Jolla is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
The upgrade on Tuesday instigated a modest rise from $24.11 to $24.51 on light volume. After a higher open in today's session ($24.51 vs. Tuesday's close of $24.51), it retreated to $24.89 before exploding to the upside then falling back under $27.
The company has missed Wall Street estimates by a wide margin in each of its last three quarters.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in